Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study. (March 2021)

• Record Type: Journal Article
• Authors: Ballesta-López, Octavio; Albert-Marí, Asunción; Borrell-García, Carmela; Melián-Sosa, Marcos; Salvador-Coloma, Carmen; Santaballa-Bertrán, Ana; Poveda-Andrés, José Luis
• Is Part Of: Journal of oncology pharmacy practice. Volume 27:Number 2(2021)
• Page Start: 268
• Page End: 278
• Publication Date: 2021-03
• Subjects: Intraperitoneal chemotherapy -- ovarian cancer -- adherence -- completion -- real life; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155220915953
• Languages: English
• ISSNs: 1078-1552

Abstract

Purpose: Intraperitoneal with intravenous chemotherapy (IP/IV) is the recommended option for patients with stage III cancer with optimally debulked (<1 cm residual) disease based on randomized controlled trials and showing important improvements in overall survival and progression free survival. However, its application has not been largely adopted due to its difficult administration that requires a trained nurse staff. The aim of this work was to study the completion and the toxicity of an IP outpatient chemotherapy regimen in optimally debulked stage III ovarian cancer patients. Methods: A single-center, retrospective observational study in women with stage III ovarian cancer following optimal cytoreductive surgery (<1 cm) followed by IP/IV chemotherapy from 2009 to 2017. The IP/IV regimen was as it follows: IV paclitaxel 175 mg/m 2 in 3 h, day 1; IP cisplatin (100 mg/m 2 —until December 2013—or 75 mg/m 2 ), day 2; IP paclitaxel 60 mg/m 2, day 8, each 21 days for six cycles. Results: A total of 60 patients received IP/IV regimen. Of these, 41 patients (68.3%) completed the six IP chemotherapy cycles and 51 (84.9%) completed four or more cycles. Most of the adverse events reported were non-hematological and G1-2. There was no difference neither in adherence nor in the frequency of adverse events between both cisplatin groups. Despite a high rate of adverse events, IP chemotherapy can be delivered with a high completion rate and manageable toxicity to patients with optimally debulked ovarian cancer.